The AKT inhibitor 'Truqap' is likely to enter the Korean market.

According to industry sources, AstraZeneca Korea has submitted an application for Truqap (capivasertib), which is used in combination with 'Faslodex (fulvestrant),' approval to the Ministry of Food and Drug Safety (MFDS), and is under review. The approval is expected to be granted within this year.

Truqap is indicated for ‘the second-line therapy or more of patients with HR-positive or HER-negative locally advanced or metastatic breast cancer who have one or more 'PIK3CA/AKT1/PTEN mutations.’

In June of last year, Truqap received a Priority Review designation from the U.S. Food and Drug Administration (FDA